The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sat., Aug. 17, 5:10 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #59. Retrophin Manchester Pharmaceuticals

Acquirer: Retrophin (NASDAQ:RTRX)
Acquiree: Manchester Pharmaceuticals
Details: Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.

Retrophin is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with rare diseases. Co. sells the following three products: Chenodal® (chenodeoxycholic acid), which is for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age; Cholbam® (cholic acid), which is for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders; and Thiola® (tiopronin), which is for the prevention of cystine (kidney) stone formation in patients with homozygous cystinuria.

RTRX SEC Filing Email Alerts Service


Open the RTRX Page at The Online Investor »

Company Name: 
Retrophin, Inc.
Website: 
www.retrophin.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding RTRX: 
22
Total Market Value Held by ETFs: 
$78.23M
Total Market Capitalization: 
$741.00M
% of Market Cap. Held by ETFs: 
10.56%
 

Open the RTRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
83rd percentile
(ranked higher than approx. 83% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 59 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.